360° Coverage : Paid COPD Clinical Trial Now Enrolling at Avail Clinical...

1 Updates

Paid COPD Clinical Trial Now Enrolling at Avail Clinical Research Near Orlando, Florida; Accepting M/F Patients with COPD Age 40+

Sep 29 2013, 11:48am CDT | by PR.com

Avail is conducting a 24-week study to evaluate the effect of a once-daily experimental inhalation therapy on arterial stiffness compared to a placebo and another drug in subjects with Chronic Obstructive Pulmonary Disease (COPD).

DeLand, FL, September 29, 2013 --(PR.com)-- To see if you qualify for this COPD Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us...

Filed under: news

YouTube Videos

 
 
 

1 year ago

Paid COPD Clinical Trial Now Enrolling at Avail Clinical Research Near Orlando, Florida; Accepting M/F Patients with COPD Age 40+

Sep 29 2013, 11:48am CDT | by PR.com

Avail is conducting a 24-week study to evaluate the effect of a once-daily experimental inhalation therapy on arterial stiffness compared to a placebo and another drug in subjects with Chronic Obstructive Pulmonary Disease (COPD).

DeLand, FL, September 29, 2013 --(PR.com)-- To see if you qualify for this COPD Clinical Trial in Florida, visit Avail Clinical Research on the web (http://www.availclinical.com) or contact us directly at (386) 785-2404. There is no cost to participate, no insurance is required, and you may receive compensation for time and travel.

Study Design
This study is designed to evaluate the effect of an experimental inhalation therapy administered once daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placebo and vilanterol over a 24 - week treatment period in subjects with COPD. Vilanterol is included to help explain relative treatment effect of this experimental inhalation therapy in the new combination, however the comparison is not powered. Arterial stiffness will be measured as aPWV. This is a randomised, placebo-controlled, multicenter study. Subjects who meet the eligibility criteria at Screening and meeting the randomisation criteria at the end of a 2-week Run-In period will enter a 24-week treatment period. There will be an approximately 7-day Follow-Up period after the treatment period.

Background & Rationale
Arterial stiffness is increasingly recognized as a surrogate marker for cardiovascular disease (CVD). In particular, arterial stiffness has been shown to be an independent predictor of future fatal and non-fatal CV events and all-cause mortality in hypertensive patients, apparently healthy elderly subjects and a general population. Arterial stiffness can be measured with non-invasive, reproducible and inexpensive techniques, which make it feasible to implement into clinical practice and large-scale clinical studies.

Primary Objectives
The primary objective of the study is to evaluate the effect of an experimental inhalation therapy administered once daily (QD) compared with placebo on aPWV in subjects with COPD and aPWV ≥ 11.0 m/s at baseline.

Inclusion Criteria
1. Type of subject: outpatient
2. Informed consent: Subjects must give their signed and dated written informed consent to participate.
3. Gender: Male or female subjects

A female is eligible to enter and participate in the study if she is of:
-Non-child bearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal or surgically sterile).
-Child bearing potential, has a negative pregnancy test at screening, and agrees to one of the following acceptable contraceptive methods used consistently and correctly:
-- Complete abstinence from intercourse from screening until the Follow-Up Phone Contact; or
-- Male partner is sterile (vasectomy with documentation of azoospermia) prior to female subject entry into the study, and this male partner is the sole partner for that subject; or
-- Implants of levonorgestrel inserted for at least 1 month prior to the study medication administration but not beyond the third successive year following insertion; or
-- Injectable progestogen administered for at least 1 month prior to study medication administration and administered until the Follow-Up Phone Contact; or
-- Oral contraceptive (combined or progestogen only) administered for at least one monthly cycle prior to study medication administration; or
-- Double barrier method: condom and occlusive cap (diaphragm or cervical/vault caps) with spermicidal agent (foam/gel/film/cream/suppository); or
-- An intrauterine device (IUD), inserted by a qualified physician, with published data showing that the highest expected failure rate is less than 1 per year; or
-- Estrogenic vaginal ring; or
-- Percutaneous contraceptive patches

4. Age: ≥40 years of age at Screening (Visit 1)
5. COPD diagnosis: Subjects with a clinical history of COPD
6. Tobacco use: Subjects with a current or prior history of ≥10 pack-years of cigarette smoking at Screening
7. Severity of Disease:

Subjects with a measured post-albuterol/salbutamol FEV1 ≤70% of predicted normal values calculated using NHANES III reference equations at Screening (Visit 1)
Subject with a measured post-albuterol/salbutamol FEV1/FVC ratio of ≤0.70 at Screening (Visit 1)
Post-bronchodilator spirometry will be performed approximately 10-15 minutes after
the subject has self-administered 4 inhalations (i.e., total 400mcg) of albuterol/salbutamol via an MDI with a valved-holding chamber.
8. Baseline aPWV: subjects with a measured aPWV≥11.0 m/s at Screening (Visit 1)

Contact Information:
Avail Clinical Research
Jennifer Economou
(386) 785-2400 336
Contact via Email
www.availclinical.com

Read the full story here: http://www.pr.com/press-release/518663

Press Release Distributed by PR.com

Source: PR.com

 

Don't miss ...

 

blog comments powered by Disqus

Latest stories

Ebola virus detected in semen three months after symptoms end
Geneva, Nov 28 (IANS/EFE) The World Health Organisation (WHO) warned Friday that the semen of men recovering from Ebola can contain the deadly virus up to three months after the symptoms disappear.
 
 
Hitachi evinces interest in developing Andhra ports
Hyderabad, Nov 28 (IANS) Japanese multinational conglomerate Hitachi has shown interest in developing ports in Andhra Pradesh.
 
 
Ebola test results now in 15 minutes!
London, Nov 28 (IANS) A 15-minute blood and saliva test for Ebola is to be tried in Guinea.
 
 
Japanese scientists develop hybrid silk using spider genes
Tokyo, Nov 28 (IANS/EFE) Japanese scientists have developed through genetic engineering using genes from spiders and silkworms a super resistant silk which could be used for textiles as well as in the surgical field, media reported Friday.
 
 
 

Latest from the Network

Indian Aces win inaugural IPTL tie
Manila, Nov 28 (IANS) The much-awaited inaugural International Premier Tennis League (IPTL) got off to a flying start with the Indian Aces notching an impressive 26-16 first victory against the Singapore Slammers at...
Read more on Sport Balla
 
Australian navy's largest ship commissioned
Canberra, Nov 28 (IANS) HMAS Canberra, a 27,000-tonne landing helicopter dock (LHD), was commissioned Friday, providing the Royal Australian Navy (RAN) with one of the world's most capable and sophisticated amphibious...
Read more on Politics Balla
 
Sindhu, Prannoy enter Macau Open semis
Macau, Nov 28 (IANS) Indian shuttlers P.V. Sindhu and H.S. Prannoy came out with contrasting wins to enter their respective semi-finals at the $120,000 Macau Open Grand Prix Gold here Friday. While defending champion...
Read more on Sport Balla
 
Ebola virus detected in semen three months after symptoms end
Geneva, Nov 28 (IANS/EFE) The World Health Organisation (WHO) warned Friday that the semen of men recovering from Ebola can contain the deadly virus up to three months after the symptoms disappear. Four studies on the...
Read more on Business Balla
 
Syria coordinating with Russia for talks with opposition
Damascus, Nov 28 (IANS) Syrian Foreign Minister Walid al-Moallem said Friday that the Syrian government is coordinating with Russia for launching a dialogue with the Syrian opposition. In an interview with the pan-...
Read more on Politics Balla
 
Two killed in Egypt clashes
Cairo, Nov 28 (IANS) Two people were killed Friday in clashes between Egyptian police and Islamist protestors in the capital Cairo. Two protestors were shot dead during the demonstrations in Matariya district and a...
Read more on Politics Balla
 
Ferguson protests expose human rights abuse in US: North Korea
Pyong Yang, Nov 28 (IANS) North Korea Friday lashed out at the US human rights record, saying the ongoing mass protests against racial discrimination exposed severe human rights abuse in the US. Protests have taken...
Read more on Politics Balla
 
US plans to release more detainees from Guantanamo Bay
Washington, Nov 28 (IANS) The Pentagon is preparing to release more prisoners from the Guantanamo Bay detention centre in Cuba, in the coming weeks, official sources in the US have revealed. According to officials,...
Read more on Politics Balla
 
Bhullar, Lahiri in fray for Indonesia Open title
Jakarta, Nov 28 (IANS) Indian golfer Gaganjeet Bhullar will be looking to defend the $750,000 Indonesia Open title against compatriot Anirban Lahiri and several others in the annual Asian Tour event at the Damai Indah...
Read more on Sport Balla
 
British court awards woman 337 mn pounds in divorce case
London, Nov 28 (IANS) Following a bitter battle, the American wife of a London financier has been awarded 337 million pounds ($529 million) by a high court judge in the largest settlement a woman has received so far in...
Read more on Politics Balla